Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study

Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study

Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs. Filgotinib is a Janus kinase 1–preferential...

Full description

Saved in:
Bibliographic Details
Main Authors: Hendrik Schulze-Koops, Tsutomu Takeuchi, Daniel Aletaha, Maya H Buch, Yoshiya Tanaka, Ricardo Blanco, Paul Emery, Jacques-Eric Gottenberg, Bernard G Combe, Roberto Caporali, Patrick Verschueren, Vijay Rajendran, Anna Zubrzycka-Sienkiewicz, Edmund V Ekoka Omoruyi, Francesco De Leonardis
Format: Article
Language:English
Published: BMJ Publishing Group 2024-10-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/10/4/e004476.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://rmdopen.bmj.com/content/10/4/e004476.full

Similar Items